Instruction 1(b).

FORM 4

Check this box if no longer subject Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

to	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person Labrucherie Gil M						NEKTAR THERAPEUTICS [NKTR]									all applicable) Director Officer (give title below)			10% Ow Other (s	ner
(Last) (First) (Middle) C/O NEKTAR THERAPEUTICS						3. Date of Earliest Transaction (Month/Day/Year) 08/26/2019									SVP & Chief Financial Officer			r	
455 MIS	SION BAY	BOULEVARD	SOUTH		\perp														
(Street) SAN FRANCISCO CA 94158				4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)								Individ ne) X	Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(S	tate)	(Zip)																
		Tak	le I - Noi	n-Deriv	vativ	e Se	curit	ies Ac	quired,	Dis	posed c	of, or Be	neficia	lly C	wned				
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)						Day/Year) it		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)			5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)
									Code	v	Amount	(A) or (D)	Price	- 1	Transact (Instr. 3 a	ion(s)			III3U. 4)
Common Stock 08/26/2						2019		М		30,00	0 A	\$16.	31	152,	872(1)		D		
		-	Table II -									or Bend ble secu		y Ov	vned		,		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Day	Date,	4. Transa Code (8)		of		6. Date Ex Expiration (Month/Da	n Date	•	le and 7. Title and Am of Securities Underlying Derivative Securities (Instr. 3 and 4)		Dei	Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)
					Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title	Amount or Number of Shares						
Stock Option	\$16.31	08/26/2019			M			30,000	12/09/201	18 1	12/08/2022	Common Stock	30,000) 4	\$0.00	57,500	0	D	

Explanation of Responses:

1. This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c).

Remarks:

Mark A. Wilson, Attorney-in-08/27/2019

Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{*} If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).